Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Breast cancer surveillance for BRCA1/2 mutation carriers - is "early detection" early enough?

Breast (Edinburgh, Scotland) - 1 Feb 2020

Bernstein-Molho Rinat, Kaufman Bella, Ben David Merav A, Sklair-Levy Miri, Feldman Dana Madoursky, Zippel Dov, Laitman Yael, Friedman Eitan

Abstract excerpt

BACKGROUND: Annual MRI screening is associated with a significant reduction in advanced-stage breast cancer diagnosis in BRCA1/2 mutation carriers. The impact that early detection has on subsequent oncological treatment is less frequently reported. In this study we compared disease stage and therapeutic approaches in BRCA1/2 mutation carriers who developed breast cancer while adhering to the recommended...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to Age of Onset

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA1 Protein

Share to BRCA2 Protein

Share to Early Detection of Cancer

Share to Neoadjuvant Therapy

Share to Neoplasm Staging

Share to Population Surveillance

Source

Open in PubMed Open full text

Identifiers

PMID: 31760168
DOI: 10.1016/j.breast.2019.10.012
PMCID: PMC7375664

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Breast cancer surveillance for BRCA1/2 mutation carriers - is "early detection" early enough?PMID 31760168Read ↗

High risk surveillance MRI may not be necessary in BRCA1/2 mutation carriers over 70 years old.Semantic proximity Read ↗

Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined.Semantic proximity Read ↗

Characteristics, treatment, and outcome of breast cancers diagnosed in BRCA1 and BRCA2 gene mutation carriers in intensive screening programs including magnetic resonance imaging.Semantic proximity Read ↗

Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study.Semantic proximity Read ↗

BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study.Semantic proximity Read ↗

Evaluating high-risk breast cancer surveillance outcomes in BRCA mutation carriers.Semantic proximity Read ↗

Breast cancer diagnosed after age 70 years in Israeli BRCA1/BRCA2 pathogenic sequence variant carriers- A single institution experienceSemantic proximity Read ↗

MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence Variations.Semantic proximity Read ↗

Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC).Semantic proximity Read ↗

Imaging Characteristics of Breast Cancers Detected During MRI-Based Surveillance in Hereditary Breast and Ovarian Cancer SyndromeSemantic proximity Read ↗

Breast Cancer Screening in Women at Higher-Than-Average Risk: Recommendations From the ACR.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.